EVLO logo

Evelo Biosciences (EVLO) Company Overview

Profile

Full Name:

Evelo Biosciences, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

May 8, 2018

Indexes:

Not included

Description:

Evelo Biosciences is a biotechnology company focused on developing treatments for diseases using a unique approach. They create therapies based on the gut microbiome, which is the collection of microorganisms in our intestines. Their goal is to improve health by harnessing the power of these microbes.

Events Calendar

Earnings

Next earnings date:

Feb 10, 2025

Recent quarterly earnings:

Nov 9, 2023

Recent annual earnings:

Mar 16, 2023
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jun 30, 2023

Analyst ratings

Recent major analysts updates

Oct 18, 23 TD Cowen
Market Perform
Jul 26, 23 Morgan Stanley
Equal-Weight
Feb 15, 23 Morgan Stanley
Equal-Weight
Nov 16, 22 Chardan Capital
Neutral
Sep 9, 22 Morgan Stanley
Equal-Weight
Aug 24, 22 Morgan Stanley
Equal-Weight
Aug 15, 22 Chardan Capital
Buy
Nov 2, 21 JMP Securities
Market Outperform
Nov 1, 21 Chardan Capital
Buy
Jun 23, 21 JMP Securities
Market Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO)
EVLO
BenzingaOctober 20, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study
Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study
Evelo (EVLO) Drops 59% on Flunking Psoriasis Drug Study
EVLO
Zacks Investment ResearchOctober 18, 2023

Evelo's (EVLO) EDP2939 fails to achieve the primary endpoint in a mid-stage for treating moderate psoriasis. The company decides to cease clinical development on the candidate.

Evelo Biosciences shares tank 46% after trial failure
Evelo Biosciences shares tank 46% after trial failure
Evelo Biosciences shares tank 46% after trial failure
EVLO
Proactive InvestorsOctober 17, 2023

Evelo Biosciences' shares have tumbled 46% in premarket trading after the biotech firm revealed disappointing results in a phase II psoriasis trial for its next-generation drug, EDP2939. A resounding miss, the treatment failed to outperform the placebo, which has no therapeutic effect.

Evelo Biosciences: May Be Worth A Small, Highly Speculative Long Position Considering Upcoming Psoriasis Phase 2 Results
Evelo Biosciences: May Be Worth A Small, Highly Speculative Long Position Considering Upcoming Psoriasis Phase 2 Results
Evelo Biosciences: May Be Worth A Small, Highly Speculative Long Position Considering Upcoming Psoriasis Phase 2 Results
EVLO
Seeking AlphaAugust 25, 2023

Following recent cash raise, EVLO has enough (barely) cash to the next catalyst, phase 2 readout in psoriasis. The event is binary and can make or break the company. Prior failure of EVLO's platform in atopic dermatitis is concerning. However, psoriasis is a different indication (different pathophysiology) and de-risked by positive results in a prior phase 2 study. Ongoing phase 2 trial in psoriasis is being conducted with a second generation candidate, EDP2939, which is expected to have better efficacy and now represents EVLO's sole clinical-stage candidate.

Why Is Evelo Biosciences (EVLO) Stock Up 51% Today?
Why Is Evelo Biosciences (EVLO) Stock Up 51% Today?
Why Is Evelo Biosciences (EVLO) Stock Up 51% Today?
EVLO
InvestorPlaceJune 20, 2023

Evelo Biosciences (NASDAQ: EVLO ) stock is rising higher on Tuesday after the clinical-stage biotechnology company reached a new standstill agreement with Horizon Technology Finance (NASDAQ: HRZN ) last week. This agreement builds on the prior one the two companies reached back in December 2022.

What Makes Evelo Biosciences, Inc. (EVLO) a New Buy Stock
What Makes Evelo Biosciences, Inc. (EVLO) a New Buy Stock
What Makes Evelo Biosciences, Inc. (EVLO) a New Buy Stock
EVLO
Zacks Investment ResearchMay 17, 2023

Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Why Is Evelo Biosciences (EVLO) Stock Up 78% Today?
Why Is Evelo Biosciences (EVLO) Stock Up 78% Today?
Why Is Evelo Biosciences (EVLO) Stock Up 78% Today?
EVLO
InvestorPlaceApril 27, 2023

Evelo Biosciences (NASDAQ: EVLO ) stock is on the rise Thursday after the company said it's shifting focus toward extracellular vesicle (EV) development. With this news, Evelo Biosciences will put a greater focus on EDP2939, which is its first EV treatment.

FAQ

  • What is the ticker symbol for Evelo Biosciences?
  • Does Evelo Biosciences pay dividends?
  • What sector is Evelo Biosciences in?
  • What industry is Evelo Biosciences in?
  • What country is Evelo Biosciences based in?
  • When did Evelo Biosciences go public?
  • Is Evelo Biosciences in the S&P 500?
  • Is Evelo Biosciences in the NASDAQ 100?
  • Is Evelo Biosciences in the Dow Jones?
  • When was Evelo Biosciences's last earnings report?
  • When does Evelo Biosciences report earnings?
  • Should I buy Evelo Biosciences stock now?

What is the ticker symbol for Evelo Biosciences?

The ticker symbol for Evelo Biosciences is NASDAQ:EVLO

Does Evelo Biosciences pay dividends?

No, Evelo Biosciences does not pay dividends

What sector is Evelo Biosciences in?

Evelo Biosciences is in the Healthcare sector

What industry is Evelo Biosciences in?

Evelo Biosciences is in the Biotechnology industry

What country is Evelo Biosciences based in?

Evelo Biosciences is headquartered in United States

When did Evelo Biosciences go public?

Evelo Biosciences's initial public offering (IPO) was on May 8, 2018

Is Evelo Biosciences in the S&P 500?

No, Evelo Biosciences is not included in the S&P 500 index

Is Evelo Biosciences in the NASDAQ 100?

No, Evelo Biosciences is not included in the NASDAQ 100 index

Is Evelo Biosciences in the Dow Jones?

No, Evelo Biosciences is not included in the Dow Jones index

When was Evelo Biosciences's last earnings report?

Evelo Biosciences's most recent earnings report was on Nov 9, 2023

When does Evelo Biosciences report earnings?

The next expected earnings date for Evelo Biosciences is Feb 10, 2025

Should I buy Evelo Biosciences stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions